Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | VDR | P11473 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10512456 | 0.98 | L3MBTL1 (0.50) | KMT2AMEN1SMN1; SMN2MITFRAB9A | |
| SCHEMBL7414768 | 0.95 | PKM (0.50) | KMT2AMEN1SMN1; SMN2MITFRAB9A | |
| SCHEMBL28075446 | 0.84 | HTR6 (0.44) | RAB9AALDH1A1PKMPOLBHTT | |
| SCHEMBL2491906 | 0.84 | MBTD1 (0.54) | KMT2AMEN1SMN1; SMN2MITFRAB9A | |
| SCHEMBL8915376 | 0.83 | L3MBTL1 (0.50) | KMT2ASMN1; SMN2L3MBTL1ALDH1A1TSHR | |
| SCHEMBL19733679 | 0.82 | MBTD1 (0.55) | KMT2AMEN1SMN1; SMN2MITFRAB9A | |
| SCHEMBL2490457 | 0.81 | L3MBTL1 (0.58) | KMT2AMEN1SMN1; SMN2MITFRAB9A | |
| Hydrochloric Acid SCHEMBL9449150 | 0.80 | L3MBTL1 (0.57) | KMT2AMEN1SMN1; SMN2MITFRAB9A | |
| SCHEMBL631561 | 0.79 | KMT2A (0.50) | KMT2AMEN1SMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL9162804 | 0.79 | L3MBTL1 (0.56) | L3MBTL1MBTD1HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0812827-A1 | Piperidine derivative as intermediates for the preparation of paroxetine and process for their preparation | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 1997-12-17 | — | — | EP | claimed |
| US-20200399255-A1 | 8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2020-12-24 | — | — | US | disclosed |
| US-20180273516-A1 | 8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2018-09-27 | — | — | US | disclosed |
| US-20170197949-A1 | 8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2017-07-13 | — | — | US | disclosed |
| US-8609673-B2 | Vandetanib derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20110117084-A1 | VANDETANIB DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2009094210-A1 | VANDETANIB DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| EP-0812827-A1 | Piperidine derivative as intermediates for the preparation of paroxetine and process for their preparation | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 1997-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117084-A1 | VANDETANIB DERIVATIVES | KDR, VHL, FLT4 | KMT2A 1953/4885MEN1 1498/4885SMN1; SMN2 4223/4885 |
| US-20170197949-A1 | 8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | KMT2A 2401/4885MEN1 3826/4885SMN1; SMN2 816/4885 |
| US-20200399255-A1 | 8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | KMT2A 2441/4885MEN1 3729/4885SMN1; SMN2 752/4885 |
| US-20180273516-A1 | 8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | OPRK1, OPRD1, OPRL1 | KMT2A 2441/4885MEN1 3729/4885SMN1; SMN2 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.